Lv5
915 积分 2021-03-22 加入
基于卫生经济学评价的我国前列腺癌筛查项目策略优化研究
2个月前
已完结
中国前列腺癌筛查研究报告（白皮书）
2个月前
已完结
恶性肿瘤骨转移及骨相关疾病临床诊疗中国专家共识
2个月前
已完结
GnRH-a妇产科临床应用专家共识
3个月前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): f inal prespecified overall survival results of a randomised, double-blind, phase 3 trial
6个月前
已完结
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
6个月前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
6个月前
已完结
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
6个月前
已完结
皖公网安备34019202002308
